Filing Flows › Penumbra (PEN) › Thrombectomy revenue
Penumbra (PEN) Thrombectomy revenue by quarter
Penumbra's Thrombectomy revenue was $279M in Q3 2026 (third quarter 2026), +8% from Q2 2026. Over the last 6 quarters it ranged from $227M (Q1 2025) to $279M (Q3 2026).
| Quarter | Thrombectomy revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $279M | +8% | +18% |
| Q2 2026 | $259M | +2% | +12% |
| Q1 2026 | $254M | +7% | +12% |
| Q3 2025 | $236M | +3% | — |
| Q2 2025 | $230M | +2% | — |
| Q1 2025 | $227M | — | — |
Q3 2026 at a glance
Penumbra, Q3 2026: revenue $410M (+16% year over year), operating margin 12.4%, net earnings $42.3M, operating cash flow $41.5M. The chart follows the revenue to costs, profit and cash.
Questions
What is Penumbra's Thrombectomy revenue?
Penumbra's Thrombectomy revenue was $279M in Q3 2026 (third quarter 2026), +8% from Q2 2026.
How has Penumbra's Thrombectomy revenue changed?
Over the last 6 quarters it ranged from $227M (Q1 2025) to $279M (Q3 2026).